---
document_datetime: 2025-06-18 11:38:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cyramza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cyramza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5531638
conversion_datetime: 2025-12-25 09:57:40.595273
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cyramza

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.3 Change(s) in the Summary of Product | 17/06/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000266389                     | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority - Accepted C.I.3.z - to update the SmPC (sections 4.8, 5.1 and 5.2) based on the outcome of Article 46 procedure (EMEA/H/C/002829/P46) in which data available from paediatric study J1S-MC-JV01 (JV01) have been assessed. In addition, the MAH took the opportunity to conduct a few editorial changes to the Danish, Dutch, Greek and Portuguese   |            |             |                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000221685 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 5.1 and 4.8 of the SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/09/2024 | SmPC and PL | SmPC new text The following text has been added to Table 7 in section 4.8 of the SmPC: Arterial thromboembolic events with frequency common The following text has been added to section 5.1 of the SmPC: A final analysis of OS, for which the study was not p owered, was performed at 297events (maturity 66.1%). The stratified OS HR was 0.98 [95% CI0.78 - 1.24, p=0.864] with a median OS |

<div style=\"page-break-after: always\"></div>

| in order to update overall survival information and add arterial thromboembolic event to the adverse drug reactions based on final results from study I4T-MC-JVCY; this is a Phase 3, Multi-Centre, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-small Cell Lung Cancer. In addition, the MAH took the opportunity to update the PI in accordance with the latest EMA excipients guideline, and to implement editorial changes to the PI.   | of 51.1months [95% CI44.85 57.26] for Cyramza plus erlotinib vs 46.0months [95% CI43.56 53.03] for placebo plus erlotinib. For more information, please refer to the Summary of Product Characteristics.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|